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Background: The worldwide increased prevalence of allergic diseases, and especially of respiratory allergy, is paralleled by
increased health costs. This requires consideration of the cost to efficacy ratio of the available treatment to identify the optimal
choice.
Objective: To compare the different economic relevance, over a long evaluation time, of symptomatic pharmacologic therapy
and sublingual immunotherapy (SLIT) in patients with allergic asthma.
Methods: Seventy patients with perennial allergic asthma, sensitized to dust mites, were enrolled; 50 of these patients were
treated with SLIT against house dust mites and 20 were treated with symptomatic drugs. The patients were evaluated for 2 years
after discontinuing immunotherapy, which was performed for 3 years, to obtain a more complete follow-up. Symptom scores,
medication scores, and all other direct medical costs were evaluated with a specific questionnaire.
Results: Patients treated with SLIT plus drugs had a higher mean annual cost in the first year of SLIT treatment compared
with patients only receiving drug treatment, but the mean annual cost became significantly lower since the end of SLIT both in
the whole population and in the subgroups defined by disease severity.
Conclusion: The economic advantage measured alongside this prospective observational study was long lasting and still
present at the fifth year of the follow-up (2 years after discontinuing SLIT) and could positively be related to the persistent good
clinical control of patients.
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INTRODUCTION
The worldwide increased prevalence of allergic diseases, and
especially of respiratory allergy, is well-known1 and is asso-
ciated with an increase of health costs,2–9 which is clearly
recognized by the National Healthcare System (NHS). Con-
sidering that the economical aspects have an impact on health
status and treatment choices, physicians and prescribers are
increasingly asked to take into account the cost-effectiveness
ratio of every medical treatment, to identify the most efficient
solutions to improve patient’s health status while balancing
the management of health cost.
This is especially important for new emerging therapies for
allergy, such as specific sublingual immunotherapy (SLIT).
The clinical efficacy of SLIT is clearly demonstrated in a
number of studies by using scores measuring clinical symp-
toms and drug intake.10–12 In particular, several studies have
shown a significant reduction of drug use during SLIT, both
in allergic rhinitis and in asthma,11 but did not consider the
advantage in terms of costs.
Specifically addressed pharmacoeconomic studies on sub-
cutaneous immunotherapy (SCIT) in patients with rhinitis
and asthma have been available since the mid-1990s13–21;
recently, some studies, mostly conducted on patients with
seasonal allergy, also analyzed the effects of SLIT on health
expenditures.22–25
The aim of the present study was to estimate, during a long
period, the economic value of symptomatic drug therapy and
SLIT in adult patients with rhinitis and asthma, sensitized to
house dust mites. The main goal of the study was to evaluate
the effectiveness and the use of health resources for SLIT vs
drug therapy during a 5-year follow-up (3 years of SLIT and
2 years after its discontinuation). A secondary goal was to
evaluate the efficacy and tolerability of SLIT.
METHODS
Patients
Seventy patients from the Allergy Center of Bordighera Hos-
pital, Bordighera, Italy, were enrolled in the study. All pa-
tients had allergic rhinitis and allergic asthma, with a level of
1 to 3 according to the Global Strategy for Asthma Manage-
ment and Prevention classification,26 and were sensitized to
house dust mites. Patients were randomized by the program
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(detailed at http://www.randomization.com) into 2 groups: 20
were treated only with symptomatic drugs (group 1), and 50
were treated with SLIT to house dust mites plus drugs as
needed (group 2). This proportion was chosen to minimize
the number of patients receiving the less favorable treatment
while maintaining a sufficient number for statistical analysis.
The inclusion criteria were as follows: age of 8 to 50 years,
persistent allergic asthma for at least 2 years, skin prick test
result positive to Dermatophagoides (wheal diameter 5
mm), and positive radioallergosorbent test result for Der-
matophagoides (at least class 2). Exclusion criteria were as
follows: systemic immunological disease, congenital immu-
nodeficiency, severe systemic disease, neoplastic diseases,
severe psychological or neurologic disorders, treatment with
SCIT or SLIT in the preceding 5 years, treatment with sys-
temic steroids or -blockers, pregnancy or lactation, and
sensitization to other perennial or prolonged seasonal aller-
gens (such as Parietaria pollen) able to interfere with the
study. Sensitization to pollens with a short seasonal duration
in our area, such as cypress (11 patients), olive (10 patients),
Betulaceae (9 patients), mugwort (6 patients), and beech (4
patients), was not an exclusion criterion.
The study was approved by the Ethical Committee of
Bordighera Hospital, and all patients gave their informed
consent to the study.
Study Design
The study was prospective: at visit 1, the patients were
evaluated and included in the study; at visit 2, the random-
ization and the start of SLIT, with delivery of clinical diaries,
were scheduled. Further visits every 6 months, with evalua-
tion of clinical diaries, were performed. After discontinuing
SLIT, the visits were every 6 months, with accurate checking
of clinical diaries, but the mean costs were evaluated on an
annual basis to the purpose of the study. Patients included in
the SLIT group were treated for at least 3 years. The study
was performed between January 2002 and December 2006
and lasted for 2 years after discontinuing SLIT, with an
annual follow-up. Score cards were used to collect symptoms
and costs (ie, resources consumed). Symptom scores were
coded as follows: 0, no symptoms; 1, mild symptoms; 2,
moderate symptoms; and 3, severe symptoms. The drug in-
take score was measured, attributing 1 point for each admin-
istration. The cost was calculated, at each follow-up visit, by
the general practitioner or the specialists and by the number
of drug boxes purchased. The mean annual cost per patient
was the sum of visits, specialist’s testing (such as spirometry
and skin prick tests), specific immunotherapy, and all drugs
related to asthma treatment drugs (at NHS charge). Patients
could purchase the drugs allowed during the study in any
pharmacy, the price being the same because in Italy it is
under government control. Each resource or drug was as-
signed a unitary cost, according to the actual NHS rate lists27
or market prices.28
Treatment
The extract used for SLIT was a mix of Dermatophagoides
pteronyssinus and Dermatophagoides farinae (Staloral300;
Stallergenes, Antony, France), standardized in the index of
reactivity. SLIT was performed by the up dosing schedule
suggested by the manufacturer, with a top dose of 300 in the
index of reactivity, and subsequent maintenance treatment
was performed by administering this dose 3 days a week. The
consumption of allergen extracts was estimated at each visit
by the returned boxes.
The agents to be used as needed for drug treatment in the
control group or in association with SLIT in the study group
were as follows: cetirizine (capsules or drops); spaglumic
acid (eyedrops); oximetazoline (nasal spray); fluticasone
(topical nasal or bronchial agent); nedocromil (topical nasal
or bronchial agent); inhaled budesonide, albuterol, salmet-
erol, formoterol, and oxitropium; methylprednisolone (cap-
sules or injection); betamethasone (capsules or injection); and
theophylline (capsules).
For treatment evaluation, according to the objectives of the
study, the variables were defined as follows:
1. Evaluation of clinical efficacy: symptom scores from
patient diary (mean of the month before the visit).
2. Pharmacoeconomic evaluation: total cost per patient per
year, according to data from the patient’s cards and diaries.
3. Patient’s evaluation: visual analog scale (VAS) admin-
istered at baseline (T0) and at the end of treatment after 3
years (T3).
4. Evaluation of safety and tolerability. All events during
SLIT were classified as follows: 0, absent; 1, local reaction
(ie, local pruritus or edema); 2, mild systemic reaction (ie,
rhinitis or conjunctivitis); and 3, systemic reaction (urticaria,
asthma, Quincke edema, or anaphylaxis).
RESULTS
Table 1 describes patient demographics at T0. The 2 groups
were homogeneous for age and basal symptom scores. Dur-
ing the study, 3 patients in group 1 (treated only with drugs),
1 after 1 year and 2 after 2 years, and 2 patients in group 2
(treated with SLIT plus drugs), 1 after 1 year and 1 after 2
years, withdrew from the study for reasons unrelated to
treatment. In particular, 2 patients moved to other towns, 2
had family problems, and 1 refused to continue without
giving an explanation. Data from patients’ cards and diaries
were missing in 4 (4.0%) of 100 group 1 patients and in 13
Table 1. Demographic Data at Baseline
Category
SLIT plus
drugs
Drugs only
Sex, No. (%)
Male 27 (54) 8 (40)
Female 23 (46) 12 (60)
Age, mean (SD), y 27.98 (12.89) 28.20 (11.75)
Symptom score, mean (SD) 14.00 (3.56) 13.70 (4.04)
Abbreviation: SLIT, sublingual immunotherapy.
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(5.2%) of 250 group 2 patients; this difference was not
significant. The comparison between groups at T0 and at T3
is shown in Figure 1. At T0, there was no significant differ-
ence between group 1 and group 2, whereas at T3, those
treated with SLIT had significantly lower scores for each
indicator. Furthermore, a statistically significant difference
for bronchial, nasal, and total symptom scores was detected
between T0 and T3 in group 2, but not in group 1.
The mean patient cost per year for the whole studied
population is reported in Figure 2. Patients in group 2 (SLIT
plus drugs) had a significantly higher mean annual cost only
in the first year of treatment compared with patients in group
1. At year 2, there was no difference; and at year 3, the mean
annual cost per patient was insignificantly lower in group 2.
At years 4 and 5, the mean annual cost per patient was
significantly lower in group 2 when compared with group 1
(Fig 2).
When the incremental annual costs per patient were esti-
mated for the asthmatic patients (Table 2), the total cost at
year 5 of €3.881 for those treated with SLIT plus drugs
represented a 22.7% savings with regard to the total cost at
year 5 of €5.020 for those treated with drugs only. Such
savings tended to increase with disease severity, reaching a
value of 33.8% for severe asthmatic patients.
The evaluation of the efficacy of the intervention, through
VAS scores, is reported in Table 3. At T0, the study and
control groups did not differ by VAS score. Patients treated
with SLIT plus drugs had a statistically significant reduction
in their mean VAS score (67.5%) between T0 and T3. At
T3, their mean VAS score was significantly lower than that of
patients treated only with drugs. The patients treated only
with drugs did not show any significant trend with time.
The use of allergen extracts, as evaluated by checking the
returned boxes, was regular in all patients. Adverse reactions
in the SLIT-treated group were mild and transient, with 5
class 1 reactions (local itch or edema) and 3 class 2 reactions
(rhinitis or conjunctivitis) in 5 patients; the other 45 patients
had no adverse events.
DISCUSSION
The main health outcome of the present study on patients
with dust mite–induced rhinitis and asthma is the significant
reduction of symptom scores after 3 years of SLIT. Along the
same lines, the patients’ evaluation of treatment by VAS was
undoubtedly more favorable in the SLIT group when com-
pared with the drug-only group. Indeed, it is known that the
VAS score is correlated to symptom severity both in adults
and children29 and to more complex and demanding tools,
such as Juniper’s quality of life questionnaires.21
From the pharmacoeconomic point of view, the total an-
nual cost evaluation for the first 2 years was higher in patients
treated with SLIT plus symptomatic drugs, but since the third
year of treatment, this trend was reversed, with a higher cost
for patients treated only with drugs. Such an advantage in-
creased after the third year, at the end of SLIT treatment,
because the cost of SLIT itself was no longer present,
whereas its clinical benefits persisted for at least another 2
years (which was the total follow-up of the study).
Figure 1. Evaluation of clinical efficacy (symptom score groups before
and after sublingual immunotherapy [SLIT]). The comparison between
group 1 (treated only with drugs) and group 2 (treated with SLIT plus drugs)
at baseline (T0) and after 3 years of SLIT (T3) is shown. There was no
significant difference between the 2 groups at T0. There was a statistically
significant difference for bronchial, nasal, and global symptom scores (BSS,
NSS, and GSS, respectively) between T0 and T3 in group 2. This difference
is significant both in the intragroup analysis (T0 vs T3 for group 2) and in the
intergroup analysis (T3 vs T3 for group 2 vs group 1). ° P  .01 and * P 
.001 (differences among groups were computed by Mann-Whitney test for
independent groups).
Figure 2. Mean patient cost per year considering the whole studied
population. Comparison of mean annual cost in the 5 years of treatment
between group 1 (treated only with drugs) and group 2 (treated with sublin-
gual immunotherapy [SLIT] plus drugs). Patients of group 2 (SLIT plus
drugs) had a significantly higher mean annual cost in the first year of
treatment with SLIT compared with patients of group 1, then the mean
annual cost per patient decreased and became significantly lower after the
end of SLIT. * P  .001 (differences among groups were computed by
Mann-Whitney test for independent groups).
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Although pharmacoeconomic studies focusing on SLIT are
still few, recent data have underlined the usefulness of this
approach’s strategy in the global long-term care of patients
and health care service.30 Our current results show a substan-
tial reduction in all outcome measures during SLIT compared
with the previous period. Similarly, in a population sample of
135 children with asthma, rhinitis, and/or conjunctivitis,22
there was a positive effect on all the clinical variables eval-
uated as outcome measures (number of exacerbations, visits,
and absence from nursery or school) and also on the direct
costs (Euros spent on drugs, specialists’ visits, and SLIT) and
indirect costs (costs resulting from children’s school and
parental work loss). The average annual cost per patient was
€2,672 before SLIT initiation and €629 during SLIT. Fur-
thermore, in the asthma subanalysis involving 41 children
with SLIT and 35 controls, a substantial reduction in cost in
SLIT-treated children was shown; similar results were also
found for allergen subgroups.
In the Sublingual Immunotherapy Pollen Allergy Italy
Study, the positive influence of SLIT was evaluated in adult
patients, based on an epidemiologic model supported by data
on the use of resources and health status transitions, from 25
centers and 2,200 Italian patients.23 This study confirmed that
SLIT is more effective (both in terms of clinical improvement
and lesser disease worsening) and less expensive than symp-
tomatic therapy.23 In the Sublingual Immunotherapy in Al-
lergic Patients study, a prospective observational study, per-
formed on 382 patients allergic to grass pollen, after the first
year of SLIT, there were cost decreases for symptomatic
treatment of 22% in patients with rhinitis and of 34% in
patients with rhinitis and asthma.24
The economic aspects of SLIT have also been evaluated in
2 recent SLIT studies performed with oral tablets for grass
pollen in northern Europe31 and southern Europe.32 In the first
study, a societal perspective was adopted, and the evaluation
of cost-effectiveness of SLIT compared with use of symp-
tomatic drugs in a 9-year time horizon analysis was per-
formed in 7 northern European countries.31 In this study, the
main outcome measure was quality-adjusted life years as an
index of health-related quality of life, whereas we used a
simpler measure (VAS, recently validated in its evaluation
capacity),29 but the 2 pharmacoeconomic evaluations are in
agreement. In fact, our data support the cost-effective evi-
dence that SLIT is better than symptomatic treatment, either
producing statistically significant differences for all efficacy
end points or reducing the annual cost. Interestingly, our
results shown in Figure 2 point out the lowest annual price of
SLIT treatment, corresponding to €1.532 (333.8) and
€769.1 (74.83) in the first and third years, respectively,
compared with an annual price of €1,550 to €1,900 found in
a prospective pharmacoeconomic analysis of the tablet SLIT
preparation in patients with grass pollen–associated rhinitis
living in 4 southern European countries (Spain, France, Italy,
and Austria).32
Our results are very close to those of a study recently
conducted in France concerning a cost-efficacy analysis on
the comparison of immunotherapy (subcutaneous and sublin-
gual) and current symptomatic treatment in adults and chil-
dren with dust mite and pollen allergy.25 As expected, SLIT,
because of no need of visits for injections, yielded a higher
cost savings with regard not only to SCIT but also to drugs,
especially in pollen-allergic patients (both adults and chil-
Table 2. Incremental Annual Cost Throughout 5 Years for Asthmatic Patients, by Severity
Group
Yeara
Change at year 5, %
1 2 3 4 5
Total
SLIT plus drugs (n50) 1.532 (49) 2.584 (48) 3.353 (48) 3.629 (48) 3.881 (48)
22.7Drugs only (n20) 1.008 (19) 2.012 (17) 3.001 (17) 4.012 (17) 5.020 (17)
Asthma 1
SLIT plus drugs (n20) 1.239 (19) 2.097 (19) 2.825 (19) 3.083 (19) 3.326 (19)
9.5Drugs only (n10) 735 (9) 1.469 (8) 2.204 (8) 2.943 (8) 3.675 (8)
Asthma 2
SLIT plus drugs (n12) 1.529 (12) 2.546 (11) 3.317 (11) 3.600 (11) 3.859 (11)
28.9Drugs only (n5) 1.068 (5) 2.154 (4) 3.222 (4) 4.332 (4) 5.424 (4)
Asthma 3
SLIT plus drugs (n18) 2.025 (18) 3.451 (18) 4.284 (18) 4.582 (18) 4.841 (18)
33.8Drugs only (n5) 1.494 (5) 2.956 (5) 4.374 (5) 5.830 (5) 7.310 (5)
Abbreviation: SLIT, sublingual immunotherapy.
aAll costs are given in Euros. Numbers in parentheses indicate the number of patients at each time point.
Table 3. Patient’s Global Evaluation (VAS Score)
Variable
SLIT plus drugs
(n50)
Drugs only
(n20)
P valuea
VAS score
At baseline 7.38 (1.12) 7.75 (1.07) .77
After 3 y 2.40 (1.81) 6.35 (1.81) .001
P valuea .001 .45 NA
Abbreviations: NA, not applicable; SLIT, sublingual immunotherapy;
VAS, visual analog scale.
aObtained via Mann-Whitney test for independent groups.
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dren). From all of these studies, it is apparent that there is an
economic advantage of SLIT over standard drug treatment;
however, our results add relevant information to the eco-
nomic evaluation of SLIT because they derive from an ob-
servational study on a population of adults sensitized to
perennial allergens. In addition, in the present study, we also
found, both in the intragroup and intergroup analyses, a
statistically significant difference for bronchial, nasal, and
total symptom scores between T0 and T3 in patients treated
with SLIT plus drugs, confirming once more the clinical
efficacy of SLIT. The latter results are consistent with pre-
vious studies demonstrating the improvement effect of SLIT
on clinical symptoms. In particular, in the SLIT plus drugs
group, the significant bronchial symptom score reduction
brings evidence to the hypothesis that SLIT could be effective
on upper and lower respiratory tract symptom control in
patients with asthma and rhinitis.
Even more important is the observation concerning the
breakeven point for SLIT plus drugs strategy, in relation to
the severity of disease, which highlights the significant sav-
ings of health care resources in patients with severe disease
(ie, patients who usually generate the higher health costs).33
The safety and tolerability of SLIT are well-known,34 but
in our study they were particularly good: 43 (90%) of 48
treated patients had no adverse events and no severe reac-
tions. The relationship between safety and cost is unexplored,
but one may argue that adverse reactions, considering their
influence on patient’s management, including more drugs,
more visits, and schedule modification, are a factor to include
in future investigations.
In conclusion, SLIT, along with an improvement of symp-
tom scores and drug intake scores, effectively produces a
reduction of total annual costs in asthmatic patients, from the
third year of therapy. Not surprisingly, in the SLIT plus drugs
arm of our study, the cost of SLIT and the need to maintain
symptomatic drug treatment cause an increase of the total
annual patient cost during the first 2 years. However, the
reduction of costs from the third year on is relevant and
persists for at least 2 years after discontinuing SLIT.
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